Congressional Democrats want HHS to use march-in rights and other existing authority to lower drug prices.

100 Congressional Democrats Urge HHS to Use Existing Power to Lower Drug Prices

The U.S. Department of Health and Human Services should swiftly use its existing statutory authority—including forcing drug patent owners to license their products to others—to lower drug prices, 100 Democratic members of Congress urged HHS Secretary Xavier Becerra late last month.

“High U.S. medicine prices are the result of prescription drug corporations using their monopoly power to hike prices and pad their bottom lines,” the group of senators and representatives said in a June 23 letter to Becerra released on June 28. “Meanwhile, U.S. law forbids direct government negotiations and other restrictions on pharmaceutical pricing.”

The U.S. Department of Health and Human Services should swiftly use its existing statutory authority—including forcing drug patent owners to license their products to others—to lower drug prices, 100 Democratic members of Congress urged HHS Secretary Xavier Becerra late last month.

Please Login or Become a Paid Subscriber to View this Content

If you are already a paid subscriber, please follow the steps below.
If you are not yet a paid subscriber, please Subscribe now.
For questions about subscriptions or technical assistance, please contact Reshma Eggleston at reshma.eggleston@340breport.com.
« Read Previous Read Next »
Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors
×

*Sign up for news summaries and alerts from 340B Report

Site Footer